Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CRV431 tackles liver fibrosis
July 2018
SHARING OPTIONS:

EDISON, N.J.—ContraVir Pharmaceuticals Inc. has reported that a preclinical study of CRV431, a cyclophilin inhibitor, appeared to decrease the extent of fibrosis in an animal model by 46 percent compared to a control. Mice were treated with streptozotocin, then fed a high-fat diet. CRV431 was administered orally for eight weeks, during which time it had no effect on body weight, liver weight or blood glucose levels. Previous studies of the compound have shown it to have antiviral effects by reducing HBV DNA, surface antigen and other viral markers of HBV infections and/or liver disease.
 
“With these results, we have data indicating that CRV431 has an independent effect on reducing the formation of fibrosis that is over and above the effects on the hepatitis B virus,” James Sapirstein, CEO of ContraVir Pharmaceuticals, noted in a press release.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.